Great West Life Assurance Co. Can increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 12.9% during the 1st quarter, HoldingsChannel reports. The fund owned 484,421 shares of the company’s stock after purchasing an additional 55,417 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Zoetis were worth $48,649,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in Zoetis in the first quarter valued at $25,000. Berman Capital Advisors LLC acquired a new position in Zoetis in the fourth quarter valued at $26,000. Private Ocean LLC acquired a new position in Zoetis in the first quarter valued at $27,000. Athena Capital Advisors LLC acquired a new position in Zoetis in the fourth quarter valued at $29,000. Finally, Resources Investment Advisors Inc. acquired a new position in Zoetis in the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 90.95% of the company’s stock.
A number of research firms have commented on ZTS. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Gabelli lowered shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price objective on the stock. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Guggenheim began coverage on shares of Zoetis in a research note on Thursday. They issued a “buy” rating on the stock. Credit Suisse Group lifted their price objective on shares of Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, April 2nd. Finally, BMO Capital Markets lifted their price objective on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research note on Thursday, May 9th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $103.15.
Shares of NYSE:ZTS opened at $102.94 on Thursday. The stock has a market capitalization of $49.00 billion, a PE ratio of 32.89, a PEG ratio of 2.56 and a beta of 0.91. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $103.97.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.45 billion. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 earnings per share. On average, equities analysts predict that Zoetis Inc will post 3.48 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be issued a $0.164 dividend. This represents a $0.66 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is 21.09%.
COPYRIGHT VIOLATION WARNING: This news story was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/23/zoetis-inc-zts-shares-bought-by-great-west-life-assurance-co-can.html.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: Why do companies pay special dividends?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.